Bispecific antibody plus CAR-T therapy for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a two-step approach for people with relapsed or hard-to-treat multiple myeloma. First, you get a bispecific antibody (a drug that helps your immune system attack myeloma cells), then you receive CAR-T cell therapy (your own immune cells modified to fight the cancer). The goal is to see if this combination works well together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have multiple myeloma that has come back or not responded to standard treatments.
- You must have tried at least one immunomodulatory drug, one proteasome inhibitor, and one anti-CD38 antibody (or meet other specific criteria).
- “You must be able to have your own immune cells collected (a process called apheresis) for the CAR-T treatment.”
- Your liver, kidney, and blood counts must be within certain limits.
- You must not have active infections like hepatitis B, hepatitis C, or HIV.
- If you are of childbearing age, you must use effective birth control during treatment and for at least 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called a bispecific antibody (which helps your immune system attack myeloma cells) as a 'bridge' treatment before you receive CAR-T cell therapy. The goal is to control the disease better and improve the success of the CAR-T treatment.
This trial tests a new type of immune cell therapy using donated umbilical cord blood cells that are modified to target two proteins (BCMA and CD19) on myeloma cells. It is for people whose multiple myeloma has come back or is not responding to at least three prior treatments, including a proteasome inhibitor, an immunomodulatory drug, or an anti-CD38 antibody.
This study tests two drugs together to see if they can help people with multiple myeloma that has come back after other treatments. It aims to shrink or control the cancer and may offer a new option for patients who have already tried several therapies.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This trial tests a new CAR-T cell treatment that targets two proteins (BCMA and CD19) on myeloma cells. It is for patients whose multiple myeloma has come back or stopped responding to other treatments and has spread to tissues outside the bone marrow.
This trial tests a new CAR-T cell treatment that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is for patients whose multiple myeloma has come back or stopped responding to treatment and has spread outside the bone marrow (extramedullary disease). The goal is to see if this dual-target approach can attack the cancer more effectively.
Hear when a new Relapsed/Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.